PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/624,911 Filing Date **TRANSMITTAL** July 21, 2003 First Named Inventor **FORM** Miljenko Dumic et al. Art Unit 1623 (to be used for all correspondence after initial filing) Examiner Name Not Yet Assigned Attorney Docket Number 03818/000M728-US0 Total Number of Pages in This Submission

			<u> </u>				
	ENCLOSURES (Check all that apply)						
Fee Transr	mittal Form	Drawing(s)	After Allowance Communication to Group				
Fee /	Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendmer	nt/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
After	Final	Petition to Convert to a Provisional Application	Proprietary Information				
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter				
Extension	of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):				
Express At	pandonment Request	Request for Refund	34 References/Publications 1 International Search Report				
x Information	n Disclosure Statement	CD, Number of CD(s)					
Certified Co	opy of Priority						
Response	to Missing Parts/ Application	Remarks					
l ·	oonse to Missing Parts						
under 37 CFR 1.52 or 1.53							
	SIGNAT	URE OF APPLICANT, ATTORNEY, OF	RAGENT				
Firm DARBY & DARBY P.C.							
or Individual name Jonathan P. Mitchell, Ph.D 50,239							
Signature	Signature Toronton Mills						
Date	February 9, 2004						

Express Mail Label No.	Dated:

Docket No.: 03818/000M728-US0

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Milienko Dumic *et al*.

Application No.: 10/624,911 Confirmation No.: 7098

Filed: July 21, 2003 Art Unit: 1623

For: ORTHORHOMBIC PSEUDOPOLYMORPHS

OF 9-DEOXO-9A-AZA-9A-METHYL-9A-

HOMOERYTHROMYCIN A

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

,

Pursuant to 37 CFR 1.56, 1.97 and 1.98, attached hereto is a copy of Form PTO/SB/08 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form Form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application. This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

)

Q.

A copy of each document on the PTO/SB/08 is attached. An abstract translation of the non-English language documents is enclosed. Reference 2 is the U.S. counterpart of reference 21.

The undersigned is also enclosing herewith a copy of a Search Report mailed January 20, 2004 for the International counterpart of the present patent application (Application No. PCT/HR03/00040), in which the presently disclosed references 9, 17, and 30 were cited. A copy of International Search Report is given as Exhibit 35. Since a translation of the Search Report is also enclosed, or the Search Report utilizes conventional codes to characterize each cited reference, it is believed that the applicants in the above-identified patent application have now met the "concise explanation" requirement of 37 C.F.R. 1.98. Furthermore, the citation of these documents is not intended as an admission that the characterization of the documents in the International Search Report is correct.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

FEB 0 9 7004 pp pplication No.: 10/624,911

Dated: February 9, 2004

Respectfully submitted,.

Jonathan P. Mitchell, Ph.D.

Registration No.: 50,239

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2 Sheet

e required to respond to a confection of information diffess it contains a valid onto contains				
Complete if Known				
Application Number	10/624,911			
Filing Date	July 21, 2003			
First Named Inventor	Miljenko Dumic			
Art Unit	1623			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	03818/000M728-US0			

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
1	AA	US-6586576 B2	07-01-2003	Aronhime et al.	entire document		
2	AB	US-6528492 B1	03-04-2003	de la Torre Garcia et al.	entire document		
3	AC	US-6451990 B1	09-17-2002	Bayod Jasanada et al.	entire document		
4	AD	US-6420537 B1	07-16-2002	Bosch et al.	entire document		
5	AE	US-6365574 B2	04-02-2002	Singer et al.	entire document		
6	AF	US-6268489 B1	07-31-2001	Allen et al.	entire document		
7	AG	US-6245903 B1	06-12-2001	Karimian et al.	entire document		
8	AH	US-5869629	02-09-1999	Bayod Jasanada et al.	entire document		
9	AI	US 4517359	05-14-1985	Kobrehel et al.	entire document		
10	AJ	US-2003 0190365 A1	10-09-2003	Fergione et al.	entire document		
11 .	AK	US-2003 0165563 A1	09-04-2003	Murphy et al.	entire document		
12	AL	US-2003 0162730 A1	08-28-2003	Li et al.	entire document		
13	AM	US-2003 0139583 A1	07-24-2003	Singh et al.	entire document		
14	AN	US-2001 0047089 A1	11-29-2001	Aronhime et al.	entire publication		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
15	BA	WO 03 102009	12-11-2003	Chemi S.P.A.	entire document	
16	BB	WO 03 082889	10-09-2003	Hanmi Pharm, Co., Ltd.	entire document	
17	BC	WO 03 077830	09-25-2003	Pliva D.D.	entire document	
18	BD	WO 03 063838	08-07-2003	Pfizer Products, Inc.	entire document	
19	BE	WO 02 42315	05-30-2002	BioChemie S.A.	entire document	
20	BF	WO 02 15842 A2	02-28-2002	Wockhardt Limited	entire document	
21	BG	WO 02 10144 A1	02-07-2002	Laboratorio Silanes, S.A. De C.V.	Abstract and Amended Claims	
22	ВН	WO 02 09640 A2	02-07-2002	Wockhardt Ltd,	entire document	
23	ВІ	WO 02 094843 A1	11-28-2002	Pfizer Products, Inc.	entire document	
24	BJ	WO 02 085898	10-31-2002	Hanmi Pharm., Co., Ltd.	entire document	
25	BK	WO 01 87912 A1	11-22-2001	Ercros Industrial, S.A.	Abstract	
26	BL	WO 01 49697 A1	07-12-2001	Teva Pharmaceuticals	entire document	
27	ВМ	WO 01 00640 A1	01-04-2001	BioChemie S.A.	entire document	
28	BN	WO 00 32203	06-08-2000	Teva Pharmaceuticals USA	entire document	
29	ВО	WO 99 58541	11-18-1999	Biochemie S.A.	entire document	
30	BP	WO 94 26758	11-24-1994	Pfizer Inc.	entire document	
31	BQ	EP 1103558 A2	05-30-2001	Astur-Pharma, S.A.	entire document	
32	BR	EP 0984020 A3	03-08-2000	Apotex Inc.	entire document	
33	BS	EP 0827965 A2	03-11-1998	Astur-Pharma, S.A.	entire document	

{W:\038	Date	
18\000	Considered	



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/624,911 INFORMATION DISCLOSURE July 21, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Miljenko Dumic Art Unit 1623 (Use as many sheets as necessary) Not Yet Assigned **Examiner Name** 03818/000M728-US0

34	BT	EP 0298650 A2	02-05-1992	Pfizer, Inc.	entire document
35	BU	International Search Report for	01-20-2004	Pliva DD	entire document
		Application No.			
		PCT/HR03/00040			

2

of

Sheet

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{W:\038	Date Considered	
18\000	 Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Application No. (if known): 10/624,911

Attorney Docket No.: 03818/000M728-US0

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Airbill No in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

February 9, 2004 Date

Typed or printed name of person signing Certificate

Each paper must have its own certificate of mailing, or this certificate must identify Note: each submitted paper.

PTO/SB/08 Form (2 pages)

Information Disclosure Statement (IDS) (3 pages)

Transmittal Sheet (1 page)

34 References and 1 International Search Report

Postcard